Sign in or create an account to add this stock to your watchlist.
About Clementia Pharmaceuticals (NASDAQ:CMTA)
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$4.47 per share
Price / Book4.19
EPS (Most Recent Fiscal Year)($7.93)
Return on Equity-165.55%
Return on Assets-71.97%
Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions
What is Clementia Pharmaceuticals' stock symbol?
Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."
How were Clementia Pharmaceuticals' earnings last quarter?
Clementia Pharmaceuticals Inc (NASDAQ:CMTA) posted its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.09. View Clementia Pharmaceuticals' Earnings History.
When is Clementia Pharmaceuticals' next earnings date?
What price target have analysts set for CMTA?
5 brokerages have issued twelve-month target prices for Clementia Pharmaceuticals' stock. Their forecasts range from $23.00 to $32.00. On average, they anticipate Clementia Pharmaceuticals' stock price to reach $26.60 in the next year. View Analyst Ratings for Clementia Pharmaceuticals.
Who are some of Clementia Pharmaceuticals' key competitors?
Some companies that are related to Clementia Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), Evotec A.G. (EVTCY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), AnaptysBio (ANAB), Puma Biotechnology (PBYI), Enanta Pharmaceuticals (ENTA), Akcea Therapeutics (AKCA), Xencor (XNCR), Madrigal Pharmaceuticals (MDGL) and MyoKardia (MYOK).
Who are Clementia Pharmaceuticals' key executives?
Clementia Pharmaceuticals' management team includes the folowing people:
- Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 51)
- Mr. Michael Singer, CFO & Corp. Sec. (Age 53)
- Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 61)
- Mr. Jeffery Packman, Chief Devel. Officer (Age 51)
- Mr. Eric Grinstead, Chief Commercial Officer (Age 61)
When did Clementia Pharmaceuticals IPO?
(CMTA) raised $101 million in an initial public offering (IPO) on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners served as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.
Has Clementia Pharmaceuticals been receiving favorable news coverage?
Headlines about CMTA stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clementia Pharmaceuticals earned a coverage optimism score of 0.14 on Accern's scale. They also assigned headlines about the company an impact score of 47.13 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Clementia Pharmaceuticals' major shareholders?
Clementia Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (2.35%), Sphera Funds Management LTD. (0.63%), Artal Group S.A. (0.63%), DAFNA Capital Management LLC (0.33%), Alps Advisors Inc. (0.13%) and Birchview Capital LP (0.12%). View Institutional Ownership Trends for Clementia Pharmaceuticals.
Which institutional investors are buying Clementia Pharmaceuticals stock?
CMTA stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., DAFNA Capital Management LLC, JPMorgan Chase & Co., Sphera Funds Management LTD., Birchview Capital LP, A.R.T. Advisors LLC and Alps Advisors Inc.. View Insider Buying and Selling for Clementia Pharmaceuticals.
How do I buy shares of Clementia Pharmaceuticals?
Shares of CMTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clementia Pharmaceuticals' stock price today?
One share of CMTA stock can currently be purchased for approximately $18.74.
How big of a company is Clementia Pharmaceuticals?
Clementia Pharmaceuticals has a market capitalization of $581.39 million. The company earns $-115,450,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.
How can I contact Clementia Pharmaceuticals?
Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]
MarketBeat Community Rating for Clementia Pharmaceuticals (CMTA)MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Clementia Pharmaceuticals (NASDAQ:CMTA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Clementia Pharmaceuticals (NASDAQ CMTA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 71.24%
Clementia Pharmaceuticals (NASDAQ CMTA) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Clementia Pharmaceuticals (NASDAQ CMTA) News Headlines
Clementia Pharmaceuticals (NASDAQ:CMTA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Clementia Pharmaceuticals (NASDAQ:CMTA) Income Statement, Balance Sheet and Cash Flow Statement
Clementia Pharmaceuticals (NASDAQ CMTA) Stock Chart for Tuesday, May, 22, 2018